Strain engineering (synbio CRO)

A strain-engineering contract research organisation sells the biological catalyst rather than the product: given a target reaction or molecule, it delivers an enzyme variant or a production strain that makes the process economic. The work is organised as a design-build-test-learn cycle, and the modern differentiator is what trains the design step — proprietary experimental datasets accumulated over fifteen to twenty years rather than public sequence databases alone. The gains are measurable at process level: in one documented pharmaceutical cascade the engineered enzymes raised substrate loading from 5 g/L to 67 g/L, cut the enzyme load of one enzyme from 100 weight percent to 8 and of another from 100 to 3, shortened reaction time from 21 hours to 12, and held stereochemical purity above 99% enantiomeric and diastereomeric excess. That is the value proposition in a sentence: the same chemistry, run at an order of magnitude higher concentration with a fraction of the catalyst. The sector splits into commercial platform companies selling engineered enzymes, public-private biofoundries carrying projects from research to pre-industrial scale, and large gene-synthesis houses that grew from oligonucleotides into full molecular-biology service stacks.

The key directions of strain engineering services are:

1. Directed Evolution Platforms: integrated enzyme-engineering platforms combining machine learning, bioinformatics and laboratory workflows in a closed design-to-validation loop, trained on two decades of in-house experimental data rather than public data alone.
2. Computational Protein Design: physics-based de novo design driven by AI agents over a proprietary structured dataset, aiming at hit rates ten to a hundred times higher than mutagenesis-led screening, and carried through to manufacturability and formulation rather than stopping at a sequence.
3. Genome Editing of Production Strains: CRISPR nuclease families developed specifically to edit industrial hosts — E. coli, Bacillus, Pichia, Aspergillus — with activity across prokaryotic and eukaryotic organisms, used to optimise the chassis rather than to treat disease.
4. Public-Private Biofoundries: consortium-funded facilities that carry microbial cell-factory projects across TRL 1 to 6, covering synthetic biology, microbial resource management, bioprocess development and scale-up in one place.

Sectoral value chain#

[Target Definition] ──> [Design] ──> [Build & Screen] ──> [Strain/Enzyme Delivery]
                                              │
                                      (test data feedback)
                                              │
                                              ▼
[Industrial Process] <─── [Bioprocess Scale-Up] <─────────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Proprietary Design Datasets: the structured record of what has actually been built and measured in-house over fifteen to twenty years, which is what separates a design platform from a public-database screen.
• Closed-Loop Design-Build-Test-Learn: the engineering cycle that turns each screening round into training data for the next design round, increasingly driven by AI agents rather than manual iteration.
• Industrial-Host Genome Editing: nuclease families selected for activity in production organisms rather than in mammalian cell lines, enabling targeted edits in the chassis that actually makes the product.

The stack is organised around one loop — design, build, test, learn — with the competitive difference lying in what trains the design step and how far the provider carries the result toward manufacture.

1. Directed Evolution with Machine Learning:
   • An integrated platform connects computational design to experimental validation in one workflow, with proprietary models trained on twenty-plus years of the provider’s own experimental results rather than only on public sequence data.
   • The output is measured in process terms: a three-enzyme cascade delivering above 99% enantiomeric and diastereomeric excess while substrate loading rises from 5 g/L to 67 g/L and enzyme loads fall from 100 weight percent to 8 and to 3, with reaction time down from 21 hours to 12.
2. Physics-Based Computational Protein Design:
   • De novo design guided by physics and a proprietary structured dataset, with AI agents running the design-build-test-learn cycle, is positioned against mutagenesis and public-sequence approaches and targets hit rates ten to a hundred times higher.
   • The scope extends past the sequence: designs are validated under application-relevant conditions and taken through formulation and manufacturability, because a protein that cannot be produced or formulated is not a product.
3. Genome Editing Aimed at Industrial Hosts:
   • The BMC nuclease family, protected by a granted European patent, provides high activity across prokaryotic and eukaryotic organisms and is aimed at defined edits in the production chassis — E. coli, Bacillus, Pichia, Aspergillus — rather than at therapeutic editing.
   • This matters because the limiting factor in an industrial fermentation is usually the host’s own metabolism, not the pathway enzyme in isolation.
4. Biofoundry Infrastructure and Scale-Up:
   • A public-private biofoundry spans synthetic biology, microbial resource management, bioprocess development and scale-up in one unit across TRL 1 to 6, sustaining roughly 50 projects a year and more than 400 completed.
   • The consortium structure exists because the pre-industrial step is expensive, shared across roughly 45 to 50 members, and is the stage at which most laboratory results fail to become processes.